REN Pingda (US),РЕН Пингда (US),LIU Ji (US),ЛИУ Йи (US),UILSON Troj Edvard (US),УИЛСОН Трой Эдвард (US),LI Liansheng (US),ЛИ Лианшенг (US),CHAN Katrina (US),ЧАН Катрина (US),ROMMEL Kristian (US),РОММЕ,РОММЕЛЬ Кристиан (US)
申请号：
RU2012105071/04
公开号：
RU0002582676C2
申请日:
2010.07.15
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to new compounds of formula V-A or their pharmaceutically acceptable salts possessing the properties of PI3-kinase (phosphatidylinositol-3-kinase) activity inhibitors. The compounds can find application for treating diseases and conditions associated with PI3-kinase activity, particularly in a T-cell, B-cell, mastocyte, dendritic cell, or neutrophil. This disease represents one or more diseases specified in cancer, a bone disorder, inflammatory disease, immune disease, respiratory disease or thrombosis. Cancer represents leukaemia or lymphoma, or cancer is specified in acute myeloid leukaemia, chronic lymphocytic leukaemia and multiple myeloma, where lymphoma represents non-Hodgkin lymphoma； an inflammatory or immune disorder is asthma, allergy, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, systemic lupus erythematosus, or graft-versus-host disease. The compound of formula V-A, or its pharmaceutically acceptable salt, or a composition can be used in a combination with rapamycin. In formula V-A:B represents a group of formulawherein Wc represents phenyl, 6-merous heterocyclyl with one heteroatom specified in oxygen or nitrogen, or C3-C6cycloalkyl； q is equal to 0 or 1； R1 represents hydrogen, C1-C4alkyl or halogeno； R2 represents halogeno or C1-C4alkyl optionally substituted by halogeno； R3 represents halogeno； R9 represents hydrogen or C1-C4alkyl.EFFECT: producing the new compounds for treating the diseases or conditions associated with PI3-kinase activity.62 cl, 19 dwg, 6 tbl, 55 exНастоящее изобретение относится к новым соединениям формулы V-A или их фармацевтически приемлемым солям, обладающим свойствами ингибиторов активности PI3-киназы (фосфатидилинозитол-3-киназы). Соединения могут найти применение для лечения заболеваний и состояний, связанных с активностью РI3-киназы, в частности, в Т-клетке, В-клетке, мастоците, дендритной клетке или нейтрофиле. Т
